BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
Nomura maintains buy on Cadila Healthcare
Numura says Q3 performance was in-line with expectations at sales/EBITDA/net profit level and gross margin of 35.2 per cent was better than expectations. US to be key growth driver for Cadila over the next two years and there is a strong possibility of consensus earnings upgrades, says Nomura.